Research output

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

  • GETAID
  • D'Haens, G.
  • Vermeire, S.
  • Lambrecht, G.
  • Baert, F.
  • Bossuyt, P.
  • Pariente, B.
  • Buisson, A.
  • Bouhnik, Y.
  • Filippi, J.
  • Vander Woude, J.
  • Van Hootegem, P.
  • Moreau, J.
  • Louis, E.
  • Franchimont, D.
  • De Vos, M.
  • Mana, F.
  • Peyrin-Biroulet, L.
  • Brixi, H.
  • Allez, M.
  • Caenepeel, P.
  • Aubourg, A.
  • Oldenburg, B.
  • Pierik, M.J.

  • Gils, A.
  • Chevret, S.
  • Laharie, D.

Associated organisations

    Research areas

  • Crohn's Disease, Therapeutic Drug Monitoring, Infliximab, Mucosal Healing, INFLAMMATORY-BOWEL-DISEASE, SCHEDULED MAINTENANCE TREATMENT, RANDOMIZED-TRIAL, TROUGH LEVEL, ANTIBODIES, THERAPY, INTENSIFICATION, MULTICENTER, OUTCOMES
View graph of relations

Details

Original languageEnglish
Pages (from-to)1343-1351.e1
Number of pages10
JournalGastroenterology
Volume154
Issue number5
DOIs
Publication statusPublished - 1 Apr 2018